Form 4: NeuroPace CEO Joel Becker Reports Stock Transactions

NeuroPace's CEO, Joel Becker, reports the acquisition and disposal of company stock and stock options.

Summary

• On February 27, 2025, Joel Becker disposed of 4,506 shares of Common Stock at a price of $12.56.
• On March 10, 2025, Becker acquired 58,500 shares of Common Stock at $0, represented by restricted stock units (RSUs).
• Becker also acquired a stock option for 99,200 shares at an exercise price of $10.04 on March 10, 2025.
• Following these transactions, Becker beneficially owns 106,464 shares of Common Stock and options for 99,200 shares.
• The RSUs vest 25% on March 3, 2026, and the remaining RSUs vest in twelve equal quarterly installments thereafter.
• 25% of the shares subject to the option vest on March 3, 2026, with the remaining shares vesting in thirty-six equal consecutive monthly installments thereafter.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing primarily reports transactions, with no explicit positive or negative implications. The disposal of shares could be seen as slightly negative, but the acquisition of RSUs and options balances this out.

Positives

• The acquisition of RSUs and stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 4,506 shares by the CEO on February 27, 2025, could be interpreted negatively, although the reason for the sale is not disclosed.

Risks

• The vesting schedules for the RSUs and stock options are back weighted, meaning that the full benefit is not realized immediately, which could impact short-term motivation.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies like NeuroPace.
• Companies such as Medtronic, Boston Scientific, and Abbott also have executives who regularly report stock transactions.
• The vesting schedules for RSUs and stock options are fairly standard, with many companies using similar vesting periods to incentivize long-term performance.

Stakeholder Impact

• Shareholders may be interested in the CEO's transactions as an indicator of management's confidence in the company.
• Employees holding company stock or options will be directly affected by the vesting schedules and stock price.

Key Dates

Keywords

NeuroPace, Joel Becker, stock options, RSU, Form 4, insider trading, beneficial ownership, NPCE